Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk A/S has logged a -20.1% 52 week change, compared to 25.4% for the S&P 500 NVO has an average analyst rating of buy and is -26.9% away from its mean target price of $120.67 per share ...

Forecast issued at 4:25 pm WST on Tuesday 31 December 2024. Mostly sunny. The chance of a thunderstorm inland in the afternoon and early evening. Winds easterly 25 to 35 km/h. Overnight temperatures ...